|
|
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Irinotecan is active against metastatic colorectal cancer and interferes
with an enzyme (topoisomerase I) that is critical for DNA replication. This
study of almost 700 patients compared the standard therapy for metastatic
colorectal cancer, fluorouracil plus leucovorin, with a combination of irinotecan
plus these two agents. A third group received irinotecan alone. As compared
with the other treatments, the triple-drug combination yielded moderate,
statistically significant improvements in progression-free survival and
the tumor-response rate.
Multiple
Complex Coronary Plaques in Patients with Acute Myocardial Infarction
Acute myocardial infarction is believed to result from the rupture of a
single unstable coronary plaque; however, the development of unstable plaques
may be a widespread process. In this study, two fifths of the 253 patients
with acute myocardial infarction had angiographic evidence of multiple complex
coronary plaques, which are at risk for becoming unstable. As compared with
patients with only one complex plaque, those with multiple complex plaques
had a higher risk of recurrent acute coronary syndromes and a greater need
for repeated angioplasty or for coronary bypass surgery during the following
year.
Effect
of Growth Hormone in Children with Chronic Renal Failure
Children with chronic renal insufficiency have poor growth, and their short-term
growth improves in response to growth hormone therapy. Whether treatment
increases their adult height is not known, however. In 38 such children,
who were treated with growth hormone for an average of 5.3 years starting
at an average age of 10.4 years, the mean final height was increased by
1.4 SD over their standardized height at the start of treatment, and the
majority of children achieved adult height within the normal range.
Liver
Involvement in Hereditary Hemorrhagic Telangiectasia
Patients
with hereditary hemorrhagic telangiectasia have angiodysplastic lesions
that affect many organs. This study examined the types of liver involvement
in 19 patients with this disease. There were three distinct presentations:
high-output heart failure, portal hypertension, and biliary disease.
|
|
Interferon
Beta-1a Treatment for a First Demyelinating Event
Interferon beta is known to have benefits in the treatment of patients
with established multiple sclerosis, but it is not known whether
treatment of patients earlier in the course of this disease is of
benefit. In this trial, 383 patients with a first attack of optic
neuritis, incomplete transverse myelitis, or a brain-stem or cerebellar
syndrome were randomly assigned to receive weekly intramuscular
injections of either interferon beta-1a or placebo. All patients
had evidence on magnetic resonance imaging of prior subclinical
demyelination in the brain. After three years of follow-up, significantly
fewer patients in the interferon beta-1a group had progression to
clinically definite multiple sclerosis (cumulative probability,
35 percent, vs. 50 percent in the placebo group).
|
| |
|